Iloprost | CAS#78919-13-8

MedKoo Cat#: 318054 | Name: Iloprost

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Iloprost is a drug used to treat pulmonary arterial hypertension (PAH), scleroderma, Raynaud's phenomenon and other diseases in which the blood vessels are constricted and blood can't flow to the tissues. This damages the tissues and causes high blood pressure. Iloprost works by opening (dilating) the blood vessels to allow the blood to flow through again. Note: This product is supplied as acetone solution (10 mg /mL)

Chemical Structure

Iloprost

CAS#78919-13-8

Theoretical Analysis

MedKoo Cat#: 318054

Name: Iloprost

CAS#: 78919-13-8

Chemical Formula: C22H32O4

Exact Mass: 360.2301

Molecular Weight: 360.49

Elemental Analysis: C, 73.30; H, 8.95; O, 17.75

Price and Availability

Size	Price	Availability
5mg	USD 850.00	Ready to ship
250mg	USD 7,950.00	2 Weeks
500mg	USD 12,950.00	2 weeks
1g	USD 18,950.00	2 weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

ZK 36374; ZK-36374; ZK36374; ZK 00036374; BAY Q6256; Iloprost, Endoprost, Ilomedin, Ciloprost, Ventavis, CHEMBL494

IUPAC/Chemical Name

(5E)-5-[(3aS,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid

InChi Key

HIFJCPQKFCZDDL-ACWOEMLNSA-N

InChi Code

InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1

SMILES Code

O=C(O)CCC/C=C1C[C@@]2([H])C[C@@H](O)[C@H](/C=C/[C@@H](O)C(C)CC#CC)[C@@]2([H])C\1

Appearance

Clear solution in acetone (white Oily or waxy solid in pure form)

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in ethyl acetate (supplied pre-dissolved 10 mg/ml)

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Certificate of Analysis

View CoA: current batch, Lot#TZC60316

QC Data

View QC data: current batch, Lot#TZC60316

Safety Data Sheet (SDS)

View Safety Data Sheet (SDS)

Instruction

View handling instruction

Biological target:

Iloprost (ZK 36374; Ciloprost) is a prostacyclin (PGI2) analogue, involves in embryo development and inflammation improvement, and inhibits tumor metastasis. Iloprost can be used for peripheral vascular research.

In vitro activity:

Cells on MTA-iloprost surface showed similar viability with MTA at 1 and 14 days but enhanced cellular viability and cell spreading compared to MTA at 7 days (p < 0.05). Reference: J Dent Sci. 2022 Jan;17(1):225-232. https://pubmed.ncbi.nlm.nih.gov/35028042/

In vivo activity:

Serum from WT urethane mice treated with iloprost stimulated significantly higher PPRE activity than the WT urethane saline treated group (Figure 4). There was no difference between the Fzd9−/− urethane iloprost and urethane saline groups (Figure 4). This demonstrates that loss of Fzd9 prevents the activation of PPARG that is characteristic of iloprost chemoprevention. Reference: iScience. 2022 May 23;25(6):104442. https://pubmed.ncbi.nlm.nih.gov/35707728/

	Solvent	mg/mL	mM
Solubility
	DMF	30.0	83.22
	DMSO	62.5	173.38
	Ethanol	30.0	83.22
	PBS (pH 7.2)	1.0	2.77

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 360.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Almeshari A, Elsafadi M, Almadhari R, Mahmood A, Alsubait S, Aksel H. The additive effect of iloprost on the biological properties of Mineral trioxide aggregate on mesenchymal stem cells. J Dent Sci. 2022 Jan;17(1):225-232. doi: 10.1016/j.jds.2021.03.018. Epub 2021 May 11. PMID: 35028042; PMCID: PMC8739256. 2. Colasanti T, Stefanantoni K, Fantini C, Corinaldesi C, Vasile M, Marampon F, Di Luigi L, Antinozzi C, Sgrò P, Lenzi A, Riccieri V, Crescioli C. The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis. Int J Mol Sci. 2022 Sep 5;23(17):10150. doi: 10.3390/ijms231710150. PMID: 36077548; PMCID: PMC9456348. 3. Sompel K, Dwyer-Nield LD, Smith AJ, Elango A, Backos DS, Zhang B, Gross J, Ternyak K, Matsuda JL, Kopf K, Keith RL, Tennis MA. Iloprost requires the Frizzled-9 receptor to prevent lung cancer. iScience. 2022 May 23;25(6):104442. doi: 10.1016/j.isci.2022.104442. PMID: 35707728; PMCID: PMC9189122. 4. Tennis MA, Smith AJ, Dwyer-Nield LD, Keith RL. Intranasal Iloprost Prevents Tumors in a Murine Lung Carcinogenesis Model. Cancer Prev Res (Phila). 2022 Jan;15(1):11-16. doi: 10.1158/1940-6207.CAPR-21-0086. Epub 2021 Sep 23. PMID: 34556494; PMCID: PMC8966202.

In vitro protocol:

In vivo protocol:

1. Sompel K, Dwyer-Nield LD, Smith AJ, Elango A, Backos DS, Zhang B, Gross J, Ternyak K, Matsuda JL, Kopf K, Keith RL, Tennis MA. Iloprost requires the Frizzled-9 receptor to prevent lung cancer. iScience. 2022 May 23;25(6):104442. doi: 10.1016/j.isci.2022.104442. PMID: 35707728; PMCID: PMC9189122. 2. Tennis MA, Smith AJ, Dwyer-Nield LD, Keith RL. Intranasal Iloprost Prevents Tumors in a Murine Lung Carcinogenesis Model. Cancer Prev Res (Phila). 2022 Jan;15(1):11-16. doi: 10.1158/1940-6207.CAPR-21-0086. Epub 2021 Sep 23. PMID: 34556494; PMCID: PMC8966202.

1: Santos-Martínez LE, Moreno-Ruiz LA, Jiménez-Santos M, Olmos-Temois SG, Bojorquez-Guerrero LA, Baranda-Tovar FM. [Clinical utility of inhaled iloprost in pulmonary arterial hypertension]. Arch Cardiol Mex. 2014 Jul-Sep;84(3):202-10. doi: 10.1016/j.acmx.2014.01.003. Epub 2014 Jul 4. Review. Spanish. PubMed PMID: 25001057. 2: Mulligan C, Beghetti M. Inhaled iloprost for the control of acute pulmonary hypertension in children: a systematic review. Pediatr Crit Care Med. 2012 Jul;13(4):472-80. doi: 10.1097/PCC.0b013e31822f192b. Review. PubMed PMID: 21926655. 3: Ewert R, Gläser S, Bollmann T, Schäper C. Inhaled iloprost for therapy in pulmonary arterial hypertension. Expert Rev Respir Med. 2011 Apr;5(2):145-52. doi: 10.1586/ers.11.14. Review. PubMed PMID: 21510725. 4: John J, Palevsky H. Clinical pharmacology and efficacy of inhaled iloprost for the treatment of pulmonary arterial hypertension. Expert Rev Clin Pharmacol. 2011 Mar;4(2):197-205. doi: 10.1586/ecp.10.136. Review. PubMed PMID: 22115402. 5: Piaggesi A, Vallini V, Iacopi E, Tedeschi A, Scatena A, Goretti C, Rizzo L. Iloprost in the management of peripheral arterial disease in patients with diabetes mellitus. Minerva Cardioangiol. 2011 Feb;59(1):101-8. Review. PubMed PMID: 21285935. 6: Kharazov AF. [Randomized placebo-controlled studies of iloprost in treatment of lower limb critical ischaemia]. Angiol Sosud Khir. 2010;16(3):27-33. Review. Russian. PubMed PMID: 21280291. 7: Chen YF, Jowett S, Barton P, Malottki K, Hyde C, Gibbs JS, Pepke-Zaba J, Fry-Smith A, Roberts J, Moore D. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation. Health Technol Assess. 2009 Oct;13(49):1-320. doi: 10.3310/hta13490. Review. PubMed PMID: 19863849. 8: Erre GL, Passiu G. Antioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosis. Reumatismo. 2009 Apr-Jun;61(2):90-7. Review. PubMed PMID: 19633795. 9: Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir Rev. 2009 Mar;18(111):29-34. doi: 10.1183/09059180.00011111. Review. PubMed PMID: 20956120. 10: Krug S, Sablotzki A, Hammerschmidt S, Wirtz H, Seyfarth HJ. Inhaled iloprost for the control of pulmonary hypertension. Vasc Health Risk Manag. 2009;5(1):465-74. Review. PubMed PMID: 19475782; PubMed Central PMCID: PMC2686263. 11: Hachulla E, Launay D, Hatron PY. [Iloprost for the treatment of systemic sclerosis]. Presse Med. 2008 May;37(5 Pt 2):831-9. Epub 2007 Nov 26. Review. French. PubMed PMID: 18035518. 12: Hsu HH, Rubin LJ. Iloprost inhalation solution for the treatment of pulmonary arterial hypertension. Expert Opin Pharmacother. 2005 Sep;6(11):1921-30. Review. PubMed PMID: 16144511. 13: Baker SE, Hockman RH. Inhaled iloprost in pulmonary arterial hypertension. Ann Pharmacother. 2005 Jul-Aug;39(7-8):1265-74. Review. PubMed PMID: 15976392. 14: de Donato G, Gussoni G, de Donato G. Is it possible to improve outcome in patients undergoing surgery for acute limb ischemia? Can iloprost, a prostacyclin analogue, be helpful? Chir Ital. 2004 Nov-Dec;56(6):769-80. Review. PubMed PMID: 15771029. 15: Minder S, Fischler M, Muellhaupt B, Zalunardo MP, Jenni R, Clavien PA, Speich R. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J. 2004 Oct;24(4):703-7. Review. PubMed PMID: 15459152. 16: Wilhelm W, Grundmann U. [Iloprost. Pharmacology and clinical application during surgery]. Anaesthesist. 2004 Aug;53(8):745-7. Review. German. PubMed PMID: 15241524. 17: Aigner N, Meizer R, Stolz G, Petje G, Krasny C, Landsiedl F, Steinboeck G. Iloprost for the treatment of bone marrow edema in the hindfoot. Foot Ankle Clin. 2003 Dec;8(4):683-93. Review. PubMed PMID: 14719835. 18: Matthes J, Mathen F, Herzig S, Wassermann K. [Therapy of severe pulmonary hypertension with prostacyclin and iloprost]. Dtsch Med Wochenschr. 2001 May 25;126(21):631-7. Review. German. PubMed PMID: 11413752. 19: Pope J, Fenlon D, Thompson A, Shea B, Furst D, Wells G, Silman A. Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. 2000;(2):CD000953. Review. PubMed PMID: 10796395. 20: Cappelli R, Bicchi M, Arrigucci S, Boschi S, Guerrini M, Forconi S. [Critical ischemia in elderly patients. Evaluation of the effect of two different methods of Iloprost therapy on the efficacy, tolerance, modification of quality of life and self-sufficiency]. Minerva Cardioangiol. 1999 Mar;47(3):81-8. Review. Italian. PubMed PMID: 10389449.